NTF3 and amyotrophic lateral sclerosis: Experimental treatments using NT-3 protein or viral vectors expressing NT-3 (as well as therapies using many other growth factors) have generally failed for long-term therapy of ALS and failed primary endpoints in human clinical trials [44,45].